Search Results

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences.

Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024.

Kodiak Sciences Inc. announced that nine scientific presentations on its clinical and research pipeline programs will be made at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting, being held from May 5 – 9 in Seattle, Washington.

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy (DR) have been treated in the randomized double masked Phase 3 GLOW2 study of tarcocimab tedromer.

Kodiak Sciences Inc., reported business highlights and financial results for the quarter and year ended December 31, 2023.

Kodiak Sciences Inc., a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024.

Kodiak Sciences Inc. announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2024, at 7:30 a.m. Pacific Time.

Kodiak Sciences Inc. announced today that first time results of the KSI-501ABC Phase 1 Study will be presented at the Angiogenesis, Exudation, and Degeneration 2024 virtual meeting. KSI-501ABC is the second product candidate built on Kodiak’s Antibody Biopolymer Conjugate (ABC) Platform.

Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2023.

Kodiak Sciences Inc. (Nasdaq: KOD) announced today that management will present at the 6th Annual Evercore ISI HealthCONx Conference in Miami, Florida on Wednesday, November 29, 2023, at 3:25 p.m. Eastern Time (12:25 p.m. Pacific Time).